Cancer Biomarkers Funding Opportunities

Titlesort descending Announcement # Expiration Date Activity Code Contact
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems PAR-20-155 (R01 Clinical Trial Optional) 09/08/2022 R01 Richard Mazurchuk, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-314 (UH3 Clinical Trials Not Allowed) 10/11/2023
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) 10/11/2023
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-22-099 (R01 Clinical Trial Optional) 05/08/2025
Co-infection and Cancer PAR-20-062 (R01 Clinical Trial Not Allowed) 01/08/2023
Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection NOT-CA-20-067 (R01 Clinical Trial Not Allowed) 01/08/2023
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers NOT-CA-21-028 01/08/2024
Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions NOT-CA-20-044 05/08/2023
Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit PAR-21-335 (U24 Clinical Trial Not Allowed) 06/12/2024
Pancreatic Cancer Detection Consortium: Research Units PAR-21-334 (U01 Clinical Trial Optional) 06/12/2024
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection PAR-20-053 (R01 Clinical Trial Not Allowed) 01/08/2023
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes PAR-20-276 (R01 Clinical Trial Not Allowed) 09/08/2022
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes PAR-20-277 (R21 Clinical Trials Not Allowed) 09/08/2022